O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

D. M. Verboom; M. R.J. Varkila; B. Morrow; T. Davies; P. Ibarra de Palacios; J. Poolman; P. W.M. Hermans; E. G. Dudley; E. Roberts; O. L. Cremer; M. J.M. Bonten

doi:10.1016/j.vaccine.2021.02.031

O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

D. M. Verboom, M. R.J. Varkila, B. Morrow, T. Davies, P. Ibarra de Palacios, J. Poolman, P. W.M. Hermans, E. G. Dudley, E. Roberts, O. L. Cremer, M. J.M. Bonten

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Objectives: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. Methods: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. Results: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). Conclusions: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

Original language	English (US)
Pages (from-to)	1670-1674
Number of pages	5
Journal	Vaccine
Volume	39
Issue number	12
DOIs	https://doi.org/10.1016/j.vaccine.2021.02.031
State	Published - Mar 19 2021

All Science Journal Classification (ASJC) codes

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2021.02.031

Cite this

Verboom, D. M., Varkila, M. R. J., Morrow, B., Davies, T., Ibarra de Palacios, P., Poolman, J., Hermans, P. W. M., Dudley, E. G., Roberts, E., Cremer, O. L., & Bonten, M. J. M. (2021). O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands. Vaccine, 39(12), 1670-1674. https://doi.org/10.1016/j.vaccine.2021.02.031

@article{200bc7e62fdb447e92aedbc476baf72a,

title = "O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands",

abstract = "Objectives: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. Methods: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. Results: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). Conclusions: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.",

author = "Verboom, {D. M.} and Varkila, {M. R.J.} and B. Morrow and T. Davies and {Ibarra de Palacios}, P. and J. Poolman and Hermans, {P. W.M.} and Dudley, {E. G.} and E. Roberts and Cremer, {O. L.} and Bonten, {M. J.M.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = mar,

day = "19",

doi = "10.1016/j.vaccine.2021.02.031",

language = "English (US)",

volume = "39",

pages = "1670--1674",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

AU - Verboom, D. M.

AU - Varkila, M. R.J.

AU - Morrow, B.

AU - Davies, T.

AU - Ibarra de Palacios, P.

AU - Poolman, J.

AU - Hermans, P. W.M.

AU - Dudley, E. G.

AU - Roberts, E.

AU - Cremer, O. L.

AU - Bonten, M. J.M.

PY - 2021/3/19

Y1 - 2021/3/19

N2 - Objectives: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. Methods: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. Results: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). Conclusions: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

AB - Objectives: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease. Methods: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing. Results: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37). Conclusions: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

UR - http://www.scopus.com/inward/record.url?scp=85101642793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101642793&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2021.02.031

DO - 10.1016/j.vaccine.2021.02.031

M3 - Article

C2 - 33642161

AN - SCOPUS:85101642793

SN - 0264-410X

VL - 39

SP - 1670

EP - 1674

JO - Vaccine

JF - Vaccine

IS - 12

ER -

O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this